Psychotropic pharmacogenetics in adult populations: From basic science to clinical trials and health economics - An evidence-based overview for decision makers.

Authors

Trang Tt Truong, Juliana Lago, Jennifer Neil, Fiona A Wilkes, Russell Barnes, Malcolm Hopwood, Ajeet B Singh

Published in

The Australian and New Zealand journal of psychiatry. Pages 48674251369625. Sep 07, 2025. Epub Sep 07, 2025.

Abstract

Psychotropic pharmacogenetics (PGx) offers significant potential advancements in psychiatric care by optimising medication selection and dosing based on genetic factors. This perspective article highlights the clinical utility, health economic implications and implementation challenges of psychotropic PGx, proposing that its broader implementation could enhance patient outcomes and reduce healthcare costs. Landmark studies show that PGx-guided care results in fewer adverse drug reactions and improved medication efficacy, with substantial cost savings compared to traditional prescribing methods. However, implementation barriers persist, particularly in Australia, where knowledge gaps, limited clinical guidelines and funding constraints hinder adoption. Despite challenges such as industry bias and limited data on non-antidepressant psychotropics, robust clinical and economic evidence supports the expanded use of psychotropic PGx, with emerging combinatorial approaches offering promise for future psychiatric treatment.

PMID:
40914863
Bibliographic data and abstract were imported from PubMed on 07 Sep 2025.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.